Dr. Anz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
605 Glenwood Drive
Suite 200
Chattanooga, TN 37404Phone+1 423-698-1844Fax+1 423-624-2226
Education & Training
Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010- Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 2004 - 2007
University of South Alabama College of MedicineClass of 2004
Certifications & Licensure
TN State Medical License 2010 - 2026
GA State Medical License 2010 - 2025
AL State Medical License 2020 - 2020
NC State Medical License 2004 - 2010- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012
Clinical Trials
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
- Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL Start of enrollment: 2014 Jun 01
Publications & Presentations
PubMed
- 68 citationsFirst-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumabchlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMI...Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz
Haematologica. 2022-09-01 - 13 citationsPomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-rel...Nizar J Bahlis, David S Siegel, Gary J Schiller, Christy Samaras, Michael Sebag
Leukemia & Lymphoma. 2022-06-01 - 8 citationsPretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the i...Richard Greil, Alessandra Tedeschi, Carol Moreno, Bertrand Anz, Loree Larratt
Annals of Hematology. 2021-05-20
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
